IDEXX Historical Income Statement

IDXX Stock

USD 421.76 0.00 0.00%

Historical analysis of IDEXX Laboratories income statement accounts such as Total Revenue of 3.8 B or Gross Profit of 2.3 B can show how well IDEXX Laboratories performed in making a profits. Evaluating IDEXX Laboratories income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of IDEXX Laboratories's future profits or losses.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining IDEXX Laboratories latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether IDEXX Laboratories is a good buy for the upcoming year.

Net Income Gross Profit

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.

About IDEXX Income Statement Analysis

IDEXX Laboratories Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to IDEXX Laboratories shareholders. The income statement also shows IDEXX investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

IDEXX Laboratories Income Statement Chart

At this time, IDEXX Laboratories' Income Before Tax is fairly stable compared to the past year. Net Income is likely to rise to about 887.3 M in 2024, despite the fact that Total Other Income Expense Net is likely to grow to (34.2 M).

Total Revenue Gross Profit Other Operating Expenses Operating Income

Total Revenue

Total revenue comprises all receipts IDEXX Laboratories generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Gross Profit

Gross profit is a required income statement account that reflects total revenue of IDEXX Laboratories minus its cost of goods sold. It is profit before IDEXX Laboratories operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of IDEXX Laboratories. It is also known as IDEXX Laboratories overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Operating Income

Operating Income is the amount of profit realized from IDEXX Laboratories operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of IDEXX Laboratories is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Most accounts from IDEXX Laboratories' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into IDEXX Laboratories current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in IDEXX Laboratories. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest.

For more information on how to buy IDEXX Stock please use our How to Invest in IDEXX Laboratories guide.At this time, IDEXX Laboratories' Income Before Tax is fairly stable compared to the past year. Net Income is likely to rise to about 887.3 M in 2024, despite the fact that Total Other Income Expense Net is likely to grow to (34.2 M).

	2021	2022	2023	2024 (projected)
Gross Profit	1.9B	2.0B	2.2B	2.3B
Total Revenue	3.2B	3.4B	3.7B	3.8B

Gross Profit Total Revenue

IDEXX Laboratories income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Selling General Administrative	Selling And Marketing Expenses	Minority Interest	Net Income From Continuing Ops	Non Operating Income Net Other	Non Recurring	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.89	0.98	0.97	0.99	0.92	0.92	0.94	0.99	0.99	0.91	-0.88	0.9	0.88	0.92	0.8	0.87	0.11	0.77	-0.26	-0.5	0.69	-0.81	-0.72	0.76	0.77
Interest Expense	0.89		0.84	0.83	0.86	0.77	0.76	0.79	0.85	0.87	0.76	-0.95	0.75	0.7	0.79	0.79	0.81	0.2	0.65	-0.11	-0.37	0.58	-0.88	-0.64	0.61	0.73
Total Revenue	0.98	0.84		1.0	1.0	0.98	0.98	0.99	1.0	0.99	0.98	-0.85	0.97	0.92	0.94	0.79	0.84	0.05	0.84	-0.39	-0.59	0.76	-0.79	-0.8	0.87	0.83
Gross Profit	0.97	0.83	1.0		0.99	0.99	0.99	0.99	0.99	0.99	0.99	-0.84	0.98	0.93	0.94	0.78	0.83	0.04	0.85	-0.4	-0.61	0.78	-0.78	-0.82	0.89	0.84
Other Operating Expenses	0.99	0.86	1.0	0.99		0.96	0.96	0.97	1.0	1.0	0.96	-0.86	0.95	0.9	0.95	0.8	0.86	0.08	0.82	-0.36	-0.55	0.73	-0.8	-0.77	0.83	0.82
Operating Income	0.92	0.77	0.98	0.99	0.96		1.0	0.99	0.97	0.95	1.0	-0.79	1.0	0.93	0.91	0.74	0.78	0.0	0.86	-0.43	-0.66	0.81	-0.75	-0.84	0.93	0.84
Ebit	0.92	0.76	0.98	0.99	0.96	1.0		0.99	0.96	0.95	1.0	-0.8	1.0	0.93	0.91	0.74	0.78	0.0	0.87	-0.43	-0.66	0.81	-0.76	-0.84	0.93	0.84
Ebitda	0.94	0.79	0.99	0.99	0.97	0.99	0.99		0.98	0.96	0.99	-0.83	0.99	0.91	0.93	0.79	0.82	0.04	0.88	-0.43	-0.59	0.8	-0.79	-0.8	0.91	0.86
Cost Of Revenue	0.99	0.85	1.0	0.99	1.0	0.97	0.96	0.98		0.99	0.96	-0.86	0.96	0.91	0.94	0.8	0.85	0.07	0.82	-0.37	-0.56	0.73	-0.79	-0.77	0.83	0.82
Total Operating Expenses	0.99	0.87	0.99	0.99	1.0	0.95	0.95	0.96	0.99		0.94	-0.87	0.94	0.9	0.96	0.81	0.87	0.09	0.81	-0.35	-0.53	0.72	-0.79	-0.77	0.82	0.81
Income Before Tax	0.91	0.76	0.98	0.99	0.96	1.0	1.0	0.99	0.96	0.94		-0.78	1.0	0.93	0.91	0.73	0.77	0.0	0.86	-0.44	-0.67	0.81	-0.74	-0.84	0.93	0.83
Total Other Income Expense Net	-0.88	-0.95	-0.85	-0.84	-0.86	-0.79	-0.8	-0.83	-0.86	-0.87	-0.78		-0.78	-0.7	-0.8	-0.84	-0.84	-0.2	-0.71	0.15	0.34	-0.62	0.96	0.66	-0.64	-0.78
Net Income	0.9	0.75	0.97	0.98	0.95	1.0	1.0	0.99	0.96	0.94	1.0	-0.78		0.9	0.89	0.75	0.77	0.04	0.88	-0.49	-0.65	0.79	-0.75	-0.83	0.93	0.87
Income Tax Expense	0.88	0.7	0.92	0.93	0.9	0.93	0.93	0.91	0.91	0.9	0.93	-0.7	0.9		0.89	0.6	0.69	-0.21	0.72	-0.18	-0.71	0.86	-0.61	-0.85	0.86	0.62
Research Development	0.92	0.79	0.94	0.94	0.95	0.91	0.91	0.93	0.94	0.96	0.91	-0.8	0.89	0.89		0.78	0.83	-0.02	0.8	-0.36	-0.47	0.78	-0.7	-0.77	0.87	0.76
Selling General Administrative	0.8	0.79	0.79	0.78	0.8	0.74	0.74	0.79	0.8	0.81	0.73	-0.84	0.75	0.6	0.78		0.98	0.25	0.89	-0.39	-0.05	0.69	-0.82	-0.46	0.7	0.78
Selling And Marketing Expenses	0.87	0.81	0.84	0.83	0.86	0.78	0.78	0.82	0.85	0.87	0.77	-0.84	0.77	0.69	0.83	0.98		0.16	0.87	-0.35	-0.13	0.72	-0.79	-0.51	0.71	0.76
Minority Interest	0.11	0.2	0.05	0.04	0.08	0.0	0.0	0.04	0.07	0.09	0.0	-0.2	0.04	-0.21	-0.02	0.25	0.16		0.11	-0.03	0.2	-0.29	-0.22	0.1	-0.07	0.15
Net Income From Continuing Ops	0.77	0.65	0.84	0.85	0.82	0.86	0.87	0.88	0.82	0.81	0.86	-0.71	0.88	0.72	0.8	0.89	0.87	0.11		-0.57	-0.29	0.82	-0.73	-0.61	0.89	0.84
Non Operating Income Net Other	-0.26	-0.11	-0.39	-0.4	-0.36	-0.43	-0.43	-0.43	-0.37	-0.35	-0.44	0.15	-0.49	-0.18	-0.36	-0.39	-0.35	-0.03	-0.57		0.14	-0.2	0.21	0.25	-0.49	-0.69
Non Recurring	-0.5	-0.37	-0.59	-0.61	-0.55	-0.66	-0.66	-0.59	-0.56	-0.53	-0.67	0.34	-0.65	-0.71	-0.47	-0.05	-0.13	0.2	-0.29	0.14		-0.46	0.26	0.84	-0.58	-0.39
Tax Provision	0.69	0.58	0.76	0.78	0.73	0.81	0.81	0.8	0.73	0.72	0.81	-0.62	0.79	0.86	0.78	0.69	0.72	-0.29	0.82	-0.2	-0.46		-0.56	-0.72	0.89	0.56
Interest Income	-0.81	-0.88	-0.79	-0.78	-0.8	-0.75	-0.76	-0.79	-0.79	-0.79	-0.74	0.96	-0.75	-0.61	-0.7	-0.82	-0.79	-0.22	-0.73	0.21	0.26	-0.56		0.55	-0.6	-0.81
Net Interest Income	-0.72	-0.64	-0.8	-0.82	-0.77	-0.84	-0.84	-0.8	-0.77	-0.77	-0.84	0.66	-0.83	-0.85	-0.77	-0.46	-0.51	0.1	-0.61	0.25	0.84	-0.72	0.55		-0.81	-0.66
Reconciled Depreciation	0.76	0.61	0.87	0.89	0.83	0.93	0.93	0.91	0.83	0.82	0.93	-0.64	0.93	0.86	0.87	0.7	0.71	-0.07	0.89	-0.49	-0.58	0.89	-0.6	-0.81		0.76
Extraordinary Items	0.77	0.73	0.83	0.84	0.82	0.84	0.84	0.86	0.82	0.81	0.83	-0.78	0.87	0.62	0.76	0.78	0.76	0.15	0.84	-0.69	-0.39	0.56	-0.81	-0.66	0.76

Click cells to compare fundamentals

IDEXX Laboratories Account Relationship Matchups

IDEXX Laboratories income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	88.0M	96.0M	104.6M	111.9M	114.9M	120.7M
Interest Expense	30.6M	32.5M	29.4M	38.8M	36.0M	37.7M
Total Revenue	2.4B	2.7B	3.2B	3.4B	3.7B	3.8B
Gross Profit	1.4B	1.6B	1.9B	2.0B	2.2B	2.3B
Other Operating Expenses	1.9B	2.0B	2.3B	2.5B	2.6B	2.7B
Operating Income	552.8M	694.5M	932.0M	898.8M	1.1B	1.2B
Ebit	552.8M	694.5M	932.0M	898.8M	1.1B	1.2B
Ebitda	640.9M	790.5M	1.0B	1.0B	1.1B	1.2B
Cost Of Revenue	1.0B	1.1B	1.3B	1.4B	1.5B	1.5B
Total Operating Expenses	812.7M	876.5M	957.4M	1.1B	1.1B	1.1B
Income Before Tax	522.2M	662.0M	902.7M	860.0M	1.1B	1.1B
Total Other Income Expense Net	(30.6M)	(32.5M)	(29.4M)	(38.8M)	(36.0M)	(34.2M)
Net Income	427.7M	581.8M	744.8M	679.1M	845.0M	887.3M
Income Tax Expense	94.4M	79.9M	157.8M	180.9M	216.1M	226.9M
Research Development	133.2M	141.2M	161.0M	254.8M	191.0M	200.5M
Selling General Administrative	261.3M	300.8M	309.7M	326.2M	335.8M	171.1M
Net Income Applicable To Common Shares	427.7M	581.8M	744.8M	679.1M	781.0M	820.0M
Selling And Marketing Expenses	418.2M	434.4M	486.7M	524.5M	566.1M	292.0M
Minority Interest	125K	16K	72K	355K	1K	0.0
Net Income From Continuing Ops	427.8M	582.1M	744.8M	679.1M	822.7M	417.0M
Non Operating Income Net Other	427K	586K	434K	1.1M	958.5K	1.5M
Tax Provision	94.4M	79.9M	157.8M	180.9M	212.0M	135.0M
Interest Income	427K	586K	434K	1.1M	2.2M	3.7M
Net Interest Income	(30.6M)	(32.5M)	(29.4M)	(38.8M)	(43.6M)	(45.8M)
Reconciled Depreciation	88.0M	96.0M	104.6M	111.9M	113.9M	107.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ESRT	Empire State Realty
C	Citigroup
C	Citigroup

Additional Tools for IDEXX Stock Analysis

When running IDEXX Laboratories' price analysis, check to measure IDEXX Laboratories' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IDEXX Laboratories is operating at the current time. Most of IDEXX Laboratories' value examination focuses on studying past and present price action to predict the probability of IDEXX Laboratories' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IDEXX Laboratories' price. Additionally, you may evaluate how the addition of IDEXX Laboratories to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

IDEXX Historical Income Statement

About IDEXX Income Statement Analysis

IDEXX Laboratories Income Statement Chart

Total Revenue

Gross Profit

Other Operating Expenses

Operating Income

IDEXX Laboratories income statement Correlations

IDEXX Laboratories Account Relationship Matchups

High Positive Relationship

High Negative Relationship

IDEXX Laboratories income statement Accounts

Also Currently Popular

Additional Tools for IDEXX Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Other Operating Expenses	+ 1.0	Total Revenue
Cost Of Revenue	+ 1.0	Total Revenue
Cost Of Revenue	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income

Total Other Income Expense Net	- 0.95	Interest Expense
Interest Income	- 0.88	Interest Expense
Total Other Income Expense Net	- 0.88	Depreciation And Amortization
Total Other Income Expense Net	- 0.87	Total Operating Expenses
Total Other Income Expense Net	- 0.86	Cost Of Revenue
Total Other Income Expense Net	- 0.86	Other Operating Expenses